Background--While many clinical prediction models (CPMs) exist to guide valvular heart disease treatment decisions, the relative performance of these CPMs is largely unknown. We systematically describe the CPMs available for patients with valvular heart disease with specific attention to performance in external validations.
T reatments for patients with advanced valvular heart disease (VHD) are increasingly offered to patients with advanced age and elevated pre-procedural risk. [1] [2] [3] Clinical predictive models (CPMs) have assumed a central role in clinical decision making and current guidelines link VHD treatment decisions to predicted risk. [4] [5] [6] CPMs can potentially enhance shared decision making, 7, 8 when they perform well and are appropriately matched to the correct decisional context, though there remain major questions about how well CPMs for patients with VHD perform in external validations.
It is well recognized that many of the best known (and most widely used) CPMs for VHD were derived on patients receiving surgical interventions 9, 10 and do not accurately predict outcomes for patients treated with percutaneous interventions, 11 though they continue to be used for this purpose. While there are newer efforts to create CPMs specific to percutaneous valve interventions, the relative performance of these models and their performances in external validations remains largely unknown. Generally, the performance of CPMs has often been underreported and incompletely assessed 12 and since CPMs that perform poorly can yield misleading predictions that motivate harmful decision making, 13 it is essential that clinicians understand CPM performance before leveraging outputs to inform decisions. This is especially important for VHD treatment decisions, given the importance of these tools.
Here, using the Tufts PACE (Predictive Analytics and Comparative Effectiveness) CPM Registry, we describe the available CPMs for patients with VHD treated with percutaneous or surgical interventions. This analysis focuses on comparative model performance during external validations.
Methods

General Approach
The data that support the findings of this study are available from the corresponding author upon reasonable request. This study analyzed data from the Tufts PACE (Predictive Analytics and Comparative Effectiveness) CPM Registry, a database created to describe the CPM literature for patients at risk for and with known cardiovascular disease. The registry, which is free and available to the public at http://pace.tuftsmedicalcenter.org/cpm, encompasses a field synopsis of CPMs for patients with VHD. The methods have been previously reported. 12 Briefly, we had previously searched PubMed for English-language articles containing CPMs for cardiovascular disease published from January 1990 through 2015. We extended the search for VHD CPMs to January 2017 to include more recent CPM development (Table S1, Figure S1 ). Citations were reviewed to confirm completeness of our review. All citations and data fields were extracted in duplicate to ensure accuracy. Discrepancies were discussed until consensus was achieved.
For inclusion in the registry, articles had to meet the following criteria: (1) develop a CPM as a primary aim, (2) contain a model predicting the development of a specified clinical diagnosis (diagnostic models) or the probability of developing a clinical outcome (prognostic models), (3) contain at least 2 outcome predictors, and (4) present enough information to estimate the probability for an individual patient. Articles were excluded if they did not provide enough information to predict a patient's risk or if the described models predicted surrogate outcomes. We also excluded non-English reports, pharmacology reports, cost-effectiveness models, decision-analysis models, systematic reviews, and editorials.
Model Selection
This report focuses on CPMs predicting outcomes for patients with VHD. CPMs predicting natural history outcomes and outcomes after surgical and percutaneous procedures were included. CPMs were grouped based on underlying valve pathology and procedure. CPMs were also included if they were derived on cardiac surgery cohorts where at least 50% of patients received treatment for VHD. CPMs derived exclusively on coronary artery bypass populations were excluded.
CPM Reporting
Information was extracted on CPM derivation and reporting. Collected fields included: index clinical condition, predicted outcome, timeframe of prediction, sample size, cohort size, and number of events. We calculated the events per variable (EPV) based on the number of variables included in the model. We also extracted information on modeling method and performance with specific attention to reporting of discrimination and calibration (Table S2 ).
Validation Search
Citations for each CPM article through September 2017 were identified using Scopus and reviewed for inclusion as external validations. An external validation was defined as any evaluation of CPM performance (assessment of either discrimination or calibration) on a data set distinct from the derivation data set. 14 External validations included validations that were done on the same cohort but temporally or geographically distinct from the derivation cohort or on an entirely separate cohort. Each validation citation was reviewed by 2 investigators for inclusion and discrepancies were reviewed with an additional investigator to arrive at consensus.
Validation Reporting
Information on validation reporting was extracted, including sample size, continent of study, number of events, and reporting of measures of discrimination and calibration (Table S3 ). The validation performance analysis focused on whether CPM discrimination changed when compared with
Clinical Perspective
What Is New?
• Risk prediction is central to decision making for patients with advanced valvular heart disease; however, the performance of clinical predictive models in external validations is often substantially worse than expected based on derivation data set performance.
What Are the Clinical Implications?
• Isolated external validations appear insufficient to broadly understand the performance of valvular heart disease clinical predictive models. • There are clinical predictive models for surgical valvular heart disease interventions that perform well across multiple external validations. • The trustworthiness of transcatheter aortic valve replacement predictions is largely unknown as these models have not been widely tested in external validations. that seen in the derivation population. Because the c-statistic ranges from 0.5 (no discriminatory ability) to 1.0 (perfect discrimination), it has been rescaled as Somer's D statistic 15 (29(cÀ0.5)) so that discrimination ranges from 0 (no discrimination) to 1.0 (perfect discrimination). We describe changes on this scale because it more intuitively reflects the true changes in discriminatory power. The percentage change in discrimination [(Validation AUCÀ0.5)À(Derivation AUCÀ0.5)/(Derivation AUCÀ0.5)9100] is presented. We also document whether validations include any assessment of CPM calibration. There is currently no literature standard for assessing calibration. Given this lack of consistency and interpretability, we have only reported on whether this dimension of performance was assessed. Calibration assessment included any comparison of observed versus expected outcomes. Examples include a Hosmer-Lemeshow statistic or calibration plot. For this study we also included measures of global fit, where overall observed event rates are compared with predicted rates (ie, calibration-in-the-large).
Relatedness
To assess the similarity between the derivation population and the validation population for each validation, we created a relatedness rubric to divide validations into 2 categories -"related" and "distantly related." The rubric contained 3 domains: (1) type of intervention (ie, percutaneous or surgical), (2) percentage of the population undergoing isolated valve procedures (as opposed to valve procedures in combination with revascularization), and (3) calendar years of enrollment. We considered a validation population to be "related" if all of the following criteria were met: (1) same type of intervention (eg, both surgical populations), (2) AE 10% absolute difference in the proportion of isolated valve procedure (eg, derivation population was 100% isolated valve and validation population was 95% isolated valve), and (3) overlapping years of enrollment. Matches that did not meet all 3 criteria were deemed "distantly related."
Results
VHD CPMs
We identified 49 CPMs predicting clinical outcomes for patients with VHD, which were cited a total of 1296 times ( Table 1, Table S2 ). 7, 9, Thirty-four (69%) predict outcomes following surgical interventions, 12 (24%) predict outcomes following percutaneous interventions, and 3 (6%) predict outcomes in the absence of intervention (Table 2) . Overall, the most commonly predicted outcomes were 30-day mortality (n=14, 29%) and in-hospital mortality (n=14, 29%). Twenty-four models (46%) were derived from patients in North America, followed by 12 (23%) from Europe and 8 (15%) from Asia (Figure 1 ). The median derivation sample size was 4510 (interquartile range [IQR], 1087-18 686), median event rate was 8.3% (IQR, 4.5%-14.8%), and median EPV was 40 (IQR, 20-92) ( Table 2 ). The median number of covariates was 10 (IQR, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] .
Among models that reported a c-statistic (n=37, 76%), the overall median ROC was 0.76 (IQR, 0.72-0.78) ( Table 2) . When stratified by intervention type, the median c-statistic was 0.77 (IQR, 0.75-0.79) for CPMs predicting outcomes following surgical interventions, 0.68 (IQR, 0.67-0.74) for CPMs for percutaneous interventions, and 0.81 (IQR, 0.77-0.86) for CPMs predicting outcomes in the absence of intervention ( Table 2) .
CPMs for Isolated Valve Disease
There are 31 CPMs for isolated valve disease. Sixteen (52%) predict outcomes following surgical intervention and 12 (39%) predict outcomes following percutaneous interventions (transcatheter aortic valve replacement [TAVR], balloon aortic valvuloplasty, and percutaneous mitral balloon valvuloplasty). Three CPMs (10%) predict outcomes for patients with aortic stenosis in the absence of intervention. The median derivation sample size was 2552 (IQR, 1064-108 410) and the median age was 70 (IQR, [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] . The median number of events was 360 (IQR, 104-2021) and the median EPV was 55 (IQR, . The median event rate was 10% (IQR, 4.6%-18.3%). For the 27 (87%) models reporting discrimination, the median cstatistic was 0.74 (IQR, 0.69-0.78).
CPMs for Isolated or Multiple Valve Disease
There are 11 CPMs that predict outcomes for patients undergoing either single or multiple valve surgical procedures. The median derivation sample size was 3544 (IQR, 2297-12 079) and the median age was 60 (IQR, [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] . The median number of events was 303 (IQR, 139-507) and the median EPV was 26 (IQR, . The median event rate was 5.1% (IQR, 4.1%-9.5%). For the 10 (91%) models reporting discrimination, the median c-statistic was 0.78 (IQR, 0.76-0.79).
CPMs for Multiple Valve Disease
There are 7 CPMs that predict outcomes specifically for multiple valve surgical interventions. These CPMs include the Society of Thoracic Surgeons (STS) Multi-Valve Risk Models 43 and the median derivation sample size was 18 686 (IQR, 4510-22 861). The median number of events was 1420 (IQR, 591-1981) and the median EPV was 71 (IQR, . Median age was 70 (IQR, [70] [71] . The median event rate was 9.4% (IQR, 7.6%-11.3%). Median number of covariates was 20 (IQR, 14-23). 
CPMs for Percutaneous VHD Interventions
Since 2009, there have been 12 CPMs presented that predict outcomes following percutaneous VHD interventions. Two models predict outcomes following mitral percutaneous mitral balloon valvuloplasty. 24, 44 There were 9 CPMs that predict outcomes following TAVR with a median derivation sample size of 2130 (IQR, 10 642 552). The median age of patients in the TAVR CPMs was 82 (IQR, [82] [83] . TAVR CPMs had a median number of events of 253 (IQR, 80-704) and the median EPV was 28 (IQR, 20-70). The median event rate was 9.9% (IQR, 5.6%-15.7%). All of the CPMs predicting outcomes following TAVR reported discrimination with a median cstatistic of 0.67 (IQR, 0.66-0.72).
External Validations
Two hundred and four external validations of these CPMs were identified, of which 190 (93%) report a c-statistic. Overall, 35 (71%) of the VHD CPMs have been externally validated and 20 (37%) have been externally validated more than once. External validations were most commonly done in cohorts of patients from Europe (n=93, 46%), Asia (n=38, 19%), and North America (n=37, 18%) ( Figure 1 ). Fifty-three (26%) validations were performed on populations from the same continent as the derivation population, with a median c-statistic of 0.71 (IQR, 0.66-0.77). Seventy-one (35%) were done on populations from a different continent, with a median c-statistic of 0.68 (IQR, 0.64-0.73). External validations overall had a median c-statistic of 0.71 (IQR, 0.65-0.77) ( Table 3 ). For the models that were externally validated, we noted an overall median percentage change in discrimination of À27.1% (IQR, À49.4-À5.7). Just under two-thirds of validations (n=129) demonstrate at least a 10% relative decline in discriminatory power, and 18 (9%) showed a decline of >80%. Thirty-three (16%) validations showed CPM discrimination at or above that seen in the derivation cohort.
The distribution of number of validations was skewed towards a small number of CPMs. Two CPMs (EuroSCORE II and STS [2009] Models 9 ) accounted for 73% of the external validations. EuroSCORE II has been validated 78 times across 5 continents (Table 4 ). Validation c-statistics ranged from 0.50 to 0.95 with a median percentage change of À23.4% (range À100%-+46.7%). For the STS (2009) Models, validation c-statistics ranged from 0.50 to 0.86 ( Table 5 ). The median percentage change was À31.8% and ranged from À100% to +18%. The STS (2009) Models have been validated 70 times across 5 continents.
Of CPMs that have been validated at least 2 times (n=17) in related populations, the highest median validation c-statistic was seen for EuroSCORE II (0.82 [IQR, 0.76-0.85]), followed by the North West Quality Improvement Programme in Cardiac Interventions model (0.78 [IQR, 0.77-0.78]), and the Northern New England Aortic model (0.76 [IQR, 0.75-0.77]) ( Table 6 ).
Forty-five (22%) external validations did not report any measure of calibration. Of the 159 validations that did report calibration, 103 (65%) reported the Hosmer-Lemeshow statistic, 87 (55%) reported calibration-in-the-large, and 46 (29%) included a calibration plot. Median c-statistic was 0.71 (IQR, 0.65-0.77) for validations that reported some measure of calibration and 0.68 (IQR, 0.63-0.74) for validations that did not report any calibration.
Clinical relatedness between the development and validation populations was assessed using a novel rubric. Seventyone validations (35%) were performed on related populations, while the remaining 133 (65%) were performed on distantlyrelated populations. The median validation c-statistic was 0.73 (IQR, 0.67-0.79) for related validations and 0.70 (IQR, 0.62-0.76) for distantly-related validations (P=0.009). There was a significant difference in percentage change in discrimination: the median change in c-statistic was À12.2% (IQR, À28.3%-+2.5%) for related validations and À32.1% (IQR, À54.9%-À12.8%) for distantly-related validations (Figure 2 , P<0.0001).
CPMs that were derived on percutaneously-treated VHD populations and externally validated (n=9) underwent a total of 19 validations, almost all of which were on percutaneous populations. CPMs that were derived on surgical VHD populations and externally validated (n=25) underwent a total of 184 validations, of which 130 (71%) were on surgical populations, 52 (28%) were on percutaneous populations, and 2 (1%) were on populations including both surgical and percutaneous interventions. For validations of surgical VHD models discrimination was better when CPMs were tested on cohorts treated with surgical versus percutaneous interventions (median c-statistic 0.74 versus 0.63, P<0.001).
Of the surgical VHD CPMs validated on percutaneous populations (n=52 validations), the CPM most often validated was the STS (2009) model predicting mortality (n=27, median c-statistic 0.64 [IQR, 0.58-0.67]). EuroSCORE II (n=20) had the highest discrimination in this setting, with a median cstatistic of 0.67 (IQR, 0.55-0.71).
Discussion
Here we show that there are many CPMs available for patients with VHD and that many of these CPMs have not been externally validated. For the CPMs that have been externally Validation data is reported at the population level only; patient-level data was not available. ‡ Validation population are "related" if it meets all of the following criteria: (1) same type of intervention (eg, both surgical populations), (2) AE10% absolute difference in the proportion of isolated valve procedure (eg, derivation population was 100% isolated valve and validation population was 95% isolated valve), and (3) overlapping years of enrollment. A validation population that does not meet all 3 criteria is "distantly related." validated, models often perform substantially worse than expected based on performance in derivation data sets. Notably, isolated external validations of VHD CPMs appear insufficient for broadly understanding CPM performance in the context of specific clinical decisions as predictive models may have highly variable performance across various databases. For patients under consideration for surgical VHD interventions, there are CPMs that have been extensively validated. The fidelity of TAVR CPM predictions is largely unknown, as these models have not been widely tested in external validations. Predicted risk is central to procedural decision making for patients with VHD, however. individual risk estimates using published CPMs for VHD appear more uncertain than originally thought, especially when prediction models are derived on patients who are not closely related to the patients being treated. CPM performance (specifically discrimination) substantially degrades from the derivation population to the validation population, particularly when populations are "distantly related" with respect to procedure type (percutaneous versus open surgical), therapeutic era, and the need for concurrent revascularization. Without attention to these patient-level specifics, it is likely that there is widespread inappropriate use of CPMs that are informing treatment decisions for patients with VHD. While it is encouraging that newer models have been developed for TAVR patients, these CPMs have not been widely validated or integrated into contemporary guidelines, and have risk estimates that may become inaccurate as devices continue to improve and procedural techniques mature. The attenuated performance of these TAVR CPMs may also be related to the magnitude and significance of comorbid illnesses that are common for older treated adults and are rarely included as part of parsimonious modeling efforts. 45 More work is needed to understand these risk factors.
The decrease in discrimination that is observed in this study may be attributable to model overfitting, differences in case mix (ie, narrower populations in the validation data set), and phenotypic heterogeneity. Ultimately, the relevant performance metrics for clinicians relate to the patients they are treating (with a specific intervention), not to performance measured at the time of CPM development. Rarely, discrimination appears to improve during validations. This is likely the result of differences between the derivation population and the validation population where some models are developed on more highly selected (narrow case-mix) cohorts than they are testing on. The data presented here demonstrates that CPMs externally validated multiple times show substantial variation in performance. This strongly suggests that adequate performance demonstrated in a single external validation may be insufficient to assess the quality (and utility) of VHD CPMs and that a more tailored approach is needed to understand the trustworthiness of CPM predictions in specific settings. There is increasing recognition of the central importance of CPM calibration. Surprisingly, calibration was reported in only 78% of the external validations of VHD CPMs. There is no agreed-upon standard for reporting model calibration and no consensus on interpreting this metric. Moreover, there are well-recognized limitations to the most commonly reported measure, the Hosmer-Lemeshow statistic (eg, sample-size dependence). 46 Reporting of model calibration represents a major shortcoming in the assessment and overall trustworthiness of VHD CPMs, as adequate calibration can protect against harm. 13 48 should lead to more consistent evaluation and better reporting of this important performance metric. For currently available CPMs, it is important for clinicians to know whether predictions over-or underestimate risk when compared with observed event rates in similar patients, especially when the decision for or against a particular intervention is informed by this output (as is the case for percutaneous VHD treatments). Poor calibration can often be overcome with a variety of updating techniques that can substantially improve accuracy of predictions. 49 There is much that remains unknown about these predictive models. CPM performance has not been studied for patients treated in many areas of Eastern Europe, Asia, Central America, South America, and Africa. This is especially important considering the many regional differences in VHD etiology, access to technologies, care systems, and guidelines. [50] [51] [52] The optimal number of validations required to adequately assess CPM performance remains unknown. Ideally, CPMs are serially validated and recalibrated (if necessary) to optimize performance for specific, local clinical decision making. Without addressing these limitations, clinical decisions that leverage CPM outputs may be inaccurate and lead to harmful decisions.
This analysis offers a structure to consider which CPMs are most accurate (discrimination and calibration) and trustworthy (consistent performance in multiple external validations). For patients being considered for surgical valve interventions, EuroSCORE II (median validation c-statistic 0.82 [0.76, 0.85]), North West Quality Improvement Programme in Cardiac There are several limitations to this work. Our review was limited to CPMs that provide enough information in the published report to calculate a risk prediction for a patient. Logistic regression models that did not report a full equation or intercept were not included. Cox regression models that did not report a point score or baseline hazard were excluded. The search for de novo VHD CPMs was last run in January 2017. While newer CPMs have been developed, there is often substantial delay before the publication of subsequent external validations. Notably, we present relative changes in discrimination to more accurately document changes on a clinically relevant scale, where small decreases in the C-statistic can result in large changes in clinically relevant performance. Lastly, this study was limited in its examination of CPM calibration, which is an important measure of model performance, but often poorly reported and without a widely-accepted summary measure.
While there are numerous available CPMs for patients with VHD, many have never been externally validated, and for those that have, discriminatory performance is often much worse than originally reported. We note that CPM performance is highly dependent on the cohort selected for study, suggesting that one-off external validations may inadequately assess performance. Instead of new CPM development, robust external validations of established TAVR CPMs and an understanding of the updating techniques that best optimize model performance are needed. Table S1 . Search strategy used to identify all CVD/Cerebrovascular and VHD-specific CPMs.
All CPM Search Terms ((predict$ adj1 model$) or (predict$ adj1 instrument$) or (predict$ adj1 score$) or (predict$ adj1 index)).mp. ((prognos$ adj1 model$) or (prognos$ adj1 instrument$) or (prognos$ adj1 score$) or (prognos$ adj1 index)).mp.
((risk adj1 model$) or (risk adj1 instrument$) or (risk adj1 score$) or (risk adj1 index) or (risk assessment model or risk assessment instrument or risk assessment score)).mp. atrial fib$.mp. or exp Atrial Fibrillation/ or exp coronary artery disease/ or exp coronary disease/ or exp myocardial infarction/ or Myocardial infarct$.mp. or exp Heart Failure, Congestive/ or exp myocardial ischemia/ or exp cardiovascular diseases/ or exp Cerebrovascular Accident/ or *heart failure/ or *stroke/ or *acute coronary syndrome/ 
